Compare CMRC & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CMRC | CVRX |
|---|---|---|
| Founded | 2009 | 2000 |
| Country | United States | United States |
| Employees | 1079 | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 211.3M | 237.1M |
| IPO Year | N/A | 2021 |
| Metric | CMRC | CVRX |
|---|---|---|
| Price | $2.92 | $7.65 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | $4.88 | ★ $10.50 |
| AVG Volume (30 Days) | ★ 587.8K | 270.2K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $56,651,000.00 |
| Revenue This Year | $5.11 | $17.17 |
| Revenue Next Year | $4.50 | $17.69 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 10.45 |
| 52 Week Low | $2.41 | $4.37 |
| 52 Week High | $5.55 | $11.30 |
| Indicator | CMRC | CVRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.46 | 47.09 |
| Support Level | $2.43 | $6.70 |
| Resistance Level | $3.10 | $7.98 |
| Average True Range (ATR) | 0.19 | 0.65 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 63.95 | 48.48 |
Commerce.com Inc is engaged in offering a Software-as-a-Service (SaaS) e-commerce platform. The company's SaaS platform engages in the creation of online stores by delivering a combination of ease-of-use, enterprise functionality, and flexibility. It powers both the customers' branded ecommerce stores and their cross-channel connections to popular online marketplaces, social networks, and offline point-of-sale systems. The group operates in a single segment covering geographical areas of Americas-U.S.; Americas-other; EMEA; and APAC, of which the majority of its revenue is generated from Americas-U.S.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.